Nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels for site-specific buccal applications.

IF 3 Q2 PHARMACOLOGY & PHARMACY

Therapeutic delivery Pub Date : 2025-04-01 Epub Date: 2025-02-20 DOI:10.1080/20415990.2025.2467018

Amanda Aparecida Maia Neves Garcia, Juliana Aenishanslin, Carolina Yoshi Campos Sugio, Thais Letícia Moreira da Silva, Vanessa Migliorini Urban, Marina Tolentino Marinho, Benjamim de Melo Carvalho, Karin Hermana Neppelenbroek, Priscileila Colerato Ferrari

{"title":"Nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels for site-specific buccal applications.","authors":"Amanda Aparecida Maia Neves Garcia, Juliana Aenishanslin, Carolina Yoshi Campos Sugio, Thais Letícia Moreira da Silva, Vanessa Migliorini Urban, Marina Tolentino Marinho, Benjamim de Melo Carvalho, Karin Hermana Neppelenbroek, Priscileila Colerato Ferrari","doi":"10.1080/20415990.2025.2467018","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to develop and analyze nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels.Materials & methods: Hydrogels were characterized by in vitro and ex vivo analyses, and antifungal activity against Candida albicans.Results: The hydrogel showed high adhesiveness and retention (83.37 ± 2.05%) to the porcine oral mucosa. The drug release from complexed nystatin and chlorhexidine hydrogels was 1.5 (95 µg/cm2) and 4.0 times higher (800 µg/cm2) than non-complexed drugs. Rheological studies indicated the prevalence of elastic behavior of the formulations. Ex vivo permeation using porcine mucosa showed retention on the oral mucosa. Hydrogels with nystatin and chlorhexidine inclusion complex showed inhibition percentages of 88.87% and 91.57%, respectively, and median inhibition zones of 8 mm.Conclusion: Mucoadhesive hydrogels with inclusion complex are promising for oral lesions with greater retention at the treatment site.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"327-338"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970780/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20415990.2025.2467018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to develop and analyze nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels.

Materials & methods: Hydrogels were characterized by in vitro and ex vivo analyses, and antifungal activity against Candida albicans.

Results: The hydrogel showed high adhesiveness and retention (83.37 ± 2.05%) to the porcine oral mucosa. The drug release from complexed nystatin and chlorhexidine hydrogels was 1.5 (95 µg/cm²) and 4.0 times higher (800 µg/cm²) than non-complexed drugs. Rheological studies indicated the prevalence of elastic behavior of the formulations. Ex vivo permeation using porcine mucosa showed retention on the oral mucosa. Hydrogels with nystatin and chlorhexidine inclusion complex showed inhibition percentages of 88.87% and 91.57%, respectively, and median inhibition zones of 8 mm.

Conclusion: Mucoadhesive hydrogels with inclusion complex are promising for oral lesions with greater retention at the treatment site.

查看原文本刊更多论文

制霉菌素：β-环糊精和氯己定：β-环糊精黏附水凝胶用于特定部位的口腔应用。

背景：本研究旨在制备制霉菌素- β-环糊精和氯己定- β-环糊精黏附水凝胶并对其进行分析。材料与方法：通过体外和离体分析对水凝胶进行了表征，并对其抗白色念珠菌活性进行了研究。结果：水凝胶对猪口腔黏膜具有较高的黏附性和保留率（83.37±2.05%）。制霉菌素和氯己定水凝胶的药物释放量分别为非络合药物的1.5倍（95µg/cm2）和4.0倍（800µg/cm2）。流变学研究表明，普遍的弹性行为的配方。猪粘膜体外渗透对口腔粘膜有滞留作用。制霉菌素和氯己定包合物水凝胶的抑制率分别为88.87%和91.57%，中位抑制区为8 mm。结论：含包合物的黏附水凝胶具有较好的治疗口腔病变的效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic delivery PHARMACOLOGY & PHARMACY-

CiteScore

5.50

自引率

0.00%

发文量

期刊介绍： Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.